Global HMOs Market 2025 by Company, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global HMOs market size was valued at US$ 875 million in 2024 and is forecast to a readjusted size of USD 1820 million by 2031 with a CAGR of 11.7% during review period.
Human Milk Oligosaccharides (HMO) are a class of complex carbohydrates naturally found in human breast milk. They are composed of multiple sugar units linked by glycosidic bonds. HMOs are one of the most abundant components in human milk after fat, protein, and lactose, and their concentration is significantly higher in human milk compared to other mammals. HMOs play a crucial role in infant health, serving as prebiotics that promote the growth of beneficial bacteria, such as bifidobacteria, helping to establish a healthy gut microbiome and enhance immune system function.
HMOs vary in structure, including monosaccharides, disaccharides, trisaccharides, and longer polysaccharide chains. Different types of HMOs have distinct biological functions, helping to combat pathogen invasion, reduce inflammation, and support brain development. While HMOs are primarily found in human milk, advances in technology have made it possible to extract and synthesize these oligosaccharides through fermentation and chemical processes for use in commercial products like infant formula, functional foods, and health supplements.
With ongoing research into the benefits of HMOs in infant health and other wellness applications, the demand for human milk oligosaccharides has been steadily increasing, particularly in infant formula and adult prebiotic foods.
Market Development Opportunities and Key Drivers:
As consumer awareness of health increases, especially in regard to infant health, the market for human milk oligosaccharides (HMOs) is experiencing significant growth opportunities. In recent years, extensive research on the role of HMOs in infant health has led more infant formula manufacturers to incorporate HMOs into their products to support immune function and gut health. Additionally, HMOs have shown potential in adult health applications, particularly in maintaining gut microbiome balance and enhancing immune function, opening new growth avenues for the market. As the global population ages and the demand for functional foods rises, there is also growing demand for prebiotic products targeting adults.
Market Risks:
Despite the promising outlook for the HMO market, there are several risks. First, the production of HMOs is complex and costly, which may hinder product accessibility and price competitiveness. Second, the HMO supply chain is intricate, involving multiple stages such as raw material extraction and fermentation. Any technological challenges or disruptions in production could affect the stability of the entire supply chain. Moreover, global regulatory and standard differences may pose challenges to market expansion, particularly in terms of varying regulatory policies and certification requirements in different countries.
Market Concentration:
Currently, the HMO production market is relatively concentrated, with several leading biotech and pharmaceutical companies dominating the industry. These companies have advanced fermentation and biosynthesis technologies that enable large-scale production while maintaining high quality. However, as technology advances and the market expands, more small and medium-sized enterprises are expected to enter the market, fostering competition and innovation.
Downstream Demand Trends:
The downstream demand for HMOs is mainly concentrated in infant formula, prebiotic foods and supplements, and personalized nutrition products. As consumers increasingly demand personalized and functional nutrition products, the market for HMOs as a functional ingredient will continue to grow. Additionally, the potential for HMOs in aging populations is being recognized, particularly for supporting gut health and immune systems in elderly individuals.
Latest Technologies:
The production technology for HMOs is continually evolving, with innovations in fermentation and biosynthesis reducing production costs. Furthermore, the application of genetic engineering and synthetic biology has opened up possibilities for customized HMO production, allowing for optimized efficiency and yields through genetically modified microorganisms.
This report is a detailed and comprehensive analysis for global HMOs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global HMOs market size and forecasts, in consumption value ($ Million), 2020-2031
Global HMOs market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global HMOs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global HMOs market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for HMOs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global HMOs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott, Dupont (Inbiose), DSM (Glycom), Chr. Hansen (Jennewein), BASF, FrieslandCampina, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
HMOs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Neutral HMOs
Acidic HMOs
Market segment by Application
Food Industry
Laboratory Research
Market segment by players, this report covers
Abbott
Dupont (Inbiose)
DSM (Glycom)
Chr. Hansen (Jennewein)
BASF
FrieslandCampina
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe HMOs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of HMOs, with revenue, gross margin, and global market share of HMOs from 2020 to 2025.
Chapter 3, the HMOs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and HMOs market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of HMOs.
Chapter 13, to describe HMOs research findings and conclusion.